Share price · GOSS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GOSS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 27 Jul 2026+46.6%
- 18 May 2026-43.3%
- 23 Feb 2026-80.1%
- 6 Feb 2026-7.2%
Nothing announced by GOSS that day or the session before.
- 23 Dec 2025-12.9%
Nothing announced by GOSS that day or the session before.
- 3 Dec 2025+14.4%
Nothing announced by GOSS that day or the session before.
Share of unusual movement by asset
For each asset, the share of GOSS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PDGFR/CSF1R/KIT (multi-kinase)Small molecule | Pulmonary Arterial Hypertension |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $38M | $19M | $51M+ $0 short-term inv. | $48M-$30M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $9.2M | $26M | $41M+ $16M short-term inv. | —-$39M operating cash flow | report ↗ |
| 2026-Q1 | $17M | $43M | $41M+ $58M short-term inv. | $47M-$39M operating cash flow | report ↗ |
| 2025-Q3 | $13M | $46M | $8.9M+ $171M short-term inv. | $48M-$36M operating cash flow | report ↗ |
| 2025-Q2 | $11M | $42M | $26M+ $187M short-term inv. | $38M-$47M operating cash flow | report ↗ |
| 2025-Q1 | $9.9M | $38M | $29M+ $229M short-term inv. | $37M-$40M operating cash flow | report ↗ |
| 2024-Q3 | $9.5M | $35M | $28M+ $299M short-term inv. | $31M-$32M operating cash flow | report ↗ |
| 2024-Q2 | $96M | $35M | $87M+ $268M short-term inv. | —$116M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $32M | $39M+ $206M short-term inv. | $42M-$52M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $31M | $83M+ $246M short-term inv. | $40M-$34M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $36M | $37M+ $125M short-term inv. | $43M-$38M operating cash flow | report ↗ |
| 2023-Q1 | — | $38M | $65M+ $137M short-term inv. | $49M-$53M operating cash flow | report ↗ |
| 2022-Q3 | — | $45M | $153M+ $151M short-term inv. | $59M-$37M operating cash flow | report ↗ |
| 2022-Q2 | — | $43M | $94M+ $128M short-term inv. | $56M-$49M operating cash flow | report ↗ |
| 2022-Q1 | — | $42M | $139M+ $133M short-term inv. | $58M-$53M operating cash flow | report ↗ |
| 2021-Q3 | — | $43M | $214M+ $153M short-term inv. | $60M-$42M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $48M | $174M | $38M+ $99M short-term inv. | $43M-$171M operating cash flow | report ↗ |
For fiscal year 2025, Gossamer Bio reported revenue of $48.47M, down 57.7% YoY, with R&D spend of $174.09M, up 25.7% YoY. Cash and equivalents stood at $37.73M, and the company recorded a net loss of $170.37M, with a quarterly net burn of $170.37M.
Operationally, Gossamer is focused on advancing seralutinib for pulmonary hypertension and reported Phase 3 PROSERA topline results showing a placebo-adjusted 6MWD improvement of 13.3 meters at Week 24 (p=0.0320), which missed the prespecified alpha threshold of 0.025. The company plans to engage the FDA, including via a Type C meeting, to define a potential regulatory path forward, and has paused enrollment in the SERANATA Phase 3 study in PH-ILD while ongoing open-label extension studies continue. The report also notes the Chiesi collaboration for seralutinib and an option agreement with Respira for RT234, but provides no financial guidance.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $115M | $138M | $46M+ $248M short-term inv. | $14M-$3.5M operating cash flow | report ↗ |
| 2023-FY | $0 | $135M | $32M+ $264M short-term inv. | $45M-$159M operating cash flow | report ↗ |
| 2022-FY | $0 | $171M | $112M+ $144M short-term inv. | $57M-$187M operating cash flow | report ↗ |
| 2021-FY | — | $170M | $183M+ $142M short-term inv. | $59M-$189M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-23 | Nathan Steven D · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-23 | Cox Russell J. · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-23 | Quisel John D · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-23 | Drynan Skye · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-23 | Ciongoli Gregory Austin · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-09-23 | Daniel Thomas O · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-23 | Milligan Sandra · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |
| 2026-08-24 | Hasnain Faheem · director, President & CEO | Award / grant (derivative) | 166 | $1000.00 | $166K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 182 reporting institutions held 177.2M shares ($55.8M, 36.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Kalehua Capital Management LLC | 17,708,133 | $5.8M |
| 2 | BlackRock, Inc. | 16,826,695 | $5.5M |
| 3 | AQR CAPITAL MANAGEMENT LLC | 10,126,897 | $3.3M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 9,394,593 | $3.1M |
| 5 | ARCH Venture Management, LLC | 8,055,916 | $2.6M |
| 6 | Octagon Capital Advisors LP | 7,750,000 | $2.5M |
| 7 | SAMSARA BIOCAPITAL, LLC | 7,222,559 | $2.4M |
| 8 | Balyasny Asset Management L.P. | 5,922,298 | $1.9M |
| 9 | Siren, L.L.C. | 5,208,968 | $1.7M |
| 10 | 683 Capital Management, LLC | 5,000,000 | $1.6M |
| 11 | HHLR ADVISORS, LTD. | 4,974,041 | $1.6M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 4,939,691 | $1.6M |
| 13 | Qube Research & Technologies Ltd | 4,917,763 | $1.6M |
| 14 | TWO SIGMA INVESTMENTS, LP | 4,780,851 | $1.6M |
| 15 | STATE STREET CORP | 4,388,109 | $1.4M |